logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Proximagen Limited


USPTO Granted Patents = 38

% Expired Patents = 76.3



Trademarks = 2

Forward Citations = 76

Loading Chart...
Loading Chart...

49 inventors (with patents filed for the assignee):

goldMedal Edward Savory (22 out of 27 patents)

silverMedal Iain Simpson (16 out of 25 patents)

bronzeMedal Lee Patient (15 out of 17 patents)

4.  David Evans (11 out of 16 patents)

5.  Michael Higginbottom (10 out of 17 patents)

6.  Max Espensen (9 out of 9 patents)

7.  Kathryn Oliver (8 out of 10 patents)

8.  Viet-Anh Anne Horgan (5 out of 9 patents)

9.  Alison Stewart (5 out of 5 patents)

10.  Allison Carley (5 out of 5 patents)

11.  Andrew Lightfoot (4 out of 11 patents)

12.  Kevin Dinnell (4 out of 15 patents)

13.  Giles Brown (3 out of 3 patents)

14.  Andrew Graham Cole (3 out of 11 patents)

15.  Peter Richardson (2 out of 5 patents)


Core Competencies:
SSAO Inhibitors
CXCR4 Antagonists
Cancer Therapies
Imidazo Compounds
Pyridine Derivatives
Alpha-7 Modulators
Neurodegeneration Treatment
Inflammation Compounds
Pro-drug Compounds
Enzyme Inhibitors
Amino Acid Derivatives
Indole Derivatives

38 patents:

1. 11530208 - Imidazo[4,5-C]pyridine derived SSAO inhibitors (2022-12-20),
2. 11512082 - Substituted imidazo[4,5-c]pyridine compounds and compositions thereof (2022-11-29),
3. 11369616 - Drug combination and its use in therapy (2022-06-28),
4. 11311552 - Therapies for cancer (2022-04-26),
5. 10995091 - CXCR4 receptor antagonists (2021-05-04),
6. 10968223 - Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors (2021-04-06),
7. 10766897 - Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors (2020-09-08),
8. 10738044 - Therapeutic compound and use in therapy (2020-08-11),
9. 10590125 - Compounds (2020-03-17),
10. 10428066 - Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (2019-10-01),
11. 10155761 - CXCR4 receptor antagonists (2018-12-18),
12. 10065954 - Substituted imidazo[4,5-c]pyridines as SSAO inhibitors (2018-09-04),
13. 9951068 - Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (2018-04-24),
14. 9890160 - Compounds I (2018-02-13),
15. 9676769 - Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (2017-06-13),
Company Overview
Proximagen Limited is a biotechnology company based in Cambridge, UK, specializing in the development of innovative therapeutics for neurological disorders. The organization focuses on advancing drug discovery and development processes, leveraging cutting-edge research to address unmet medical needs in the field of neuroscience. With a commitment to improving patient outcomes, Proximagen collaborates with various stakeholders to bring novel treatments from the lab to clinical application, aiming to enhance the quality of life for individuals affected by these conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

38 Patents

#28 in Cambridge

#471 in United Kingdom

#17,831 in the World

Cambridge, GB
Cambridge, United Kingdom

Proximagen Limited

Forward Citations = 76

49 inventors:

goldMedal Edward Savory (22 out of 27 patents)

silverMedal Iain Simpson (16 out of 25 patents)

bronzeMedal Lee Patient (15 out of 17 patents)

4.  David Evans (11 out of 16 patents)

5.  Michael Higginbottom (10 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Proximagen Limited. Retrieved from https://idiyas.com/company/proximagen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…